What Attendees Can Expect from WCLC25 - IASLC / cancer, IASLC, International Association for the Study of Lung Cancer, Isabelle Schmitt-Opitz, Jarushka

Jarushka Naidoo Shares Duncan Preece’s Patient-Focused Insights from ALK Positive Canada / ALK Positive, cancer, Duncan Preece, Jarushka Naidoo, Lung Health

We report a pilot clinical trial investigating the feasibility of liquid biopsy genotyping (LBG) at the time of radiological suspicion of advanced NSCLC, incorporating a micro-cost model (MCM). (PLAsm...

YouTube video by European Society for Medical Oncology (ESMO)

This Viewpoint discusses the need to quantify the long-term adverse effects of immune checkpoint inhibitors, particularly immune-related adverse effects, which are not universally dose dependent, limi...

Abstract. Approved inhibitors of KRASG12C prevent oncogenic activation by sequestering the inactive, GDP-bound (OFF) form rather than directly binding and inhibiting the active, GTP-bound (ON) form. T...

This study examines a modified progressive disease classification and its association with postprogression survival in patients treated with atezolizumab across various solid tumors.

Abstract. Purpose: Patients with KRAS mutant non-small cell lung cancer (NSCLC) have limited therapeutic options. Based on activity of nuclear export inhibition in preclinical models, we evaluated thi...

Alectinib, a small-molecule kinase inhibitor, is used as first-line treatment for anaplastic lymphoma kinase–positive (ALK+) non-small cell lung cancer (NSCLC). Albeit generally well-tolerated, a considerable subset of patients requires dose adjustments due to drug-related toxicity. Single-nucleotide polymorphisms (SNPs) in genes related to the metabolism of alectinib may upfront identify patients at risk for toxicity.

On December 4, 2024, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) for limited-stage small cell lung cancer (LS-SCLC).

Lung cancer remains a critical public health issue, presenting multifaceted challenges in prevention, diagnosis, and treatment. This article aims to r…

ALT: a man with long hair and a beard is standing in the snow with mountains in the background .

AbstractBackground. Immune checkpoint inhibitors (ICIs) are associated with severe immune-related adverse events (s-irAEs) that result in hospitalization,

EGFR-mutant NSCLC is associated with low mutation burden and low levels of PD-L1 expression. We conducted a phase 2 trial to determine the efficacy of durvalumab, tremelimumab and platinum-pemetrexed ...

AbstractBackground. Associations between immune-related adverse events (irAEs) from checkpoint inhibitor therapy and outcomes have been previously evaluate

AbstractPurpose:. Seizure-related homolog protein 6 (SEZ6) is a novel target expressed in small cell lung cancer (SCLC). ABBV-011, a SEZ6-targeted antibody conjugated to calicheamicin, was evaluated i...

ALT: a man is talking to a woman and says my little birds are everywhere .

Chromothripsis is an extreme form of chromosome instability that causes the acquisition of multiple genomic aberrations. Simovic-Lorenz and Ernst discuss mechanistic models of chromothripsis and outli...

Don’t miss the newest articles. Keep up to date with the latest research, clinical reviews, and opinions.

Patient recruitment is challenging for clinical trials. Here, the authors introduce TrialGPT, an end-to-end framework for zero-shot patient-to-trial matching with large language models.

ALT: a close up of a woman 's face with her eyes closed

ALT: a group of people are standing in front of a window looking out .